Clinical Research Directory
Browse clinical research sites, groups, and studies.
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
Sponsor: Fudan University
Summary
The study aims to compare the efficacy and safety of S-1 for 9 months versus S-1 for 1 year as adjuvant chemotherapy after D2 resection in patients with gastric cancer. Hypothesis: For gastric patients after D2 resection, S-1 for 9 months shows non-inferiority to S-1 for 1 year in disease-free survival(DFS), overall survival (OS) and safety.
Official title: Compare S-1 for 9 Months to 1 Year as Adjuvant Chemotherapy in Stage II Gastric Cancer (SMAC)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
1006
Start Date
2019-01-01
Completion Date
2027-05-01
Last Updated
2019-05-31
Healthy Volunteers
No
Conditions
Interventions
S-1 for 9 months
S-1 for 9 months after D2 resection
S-1 for 1 year
S-1 for 1 year after D2 resection
Locations (6)
Anqing Municipal Hospital
Anqing, China
Second Affiliated Hospital, School of Medicine
Hangzhou, China
Anhui Provincial Hospital
Hefei, China
Jiangxi Provincial Cancer Hospital
Nanchang, China
Dazhi Xu
Shanghai, China
First Affiliated Hospital of Wannan Medical College
Wuhu, China